The global Immunohistochemistry Market is valued at an estimated USD 3.4 billion in 2024 and is projected to reach USD 5.2 ...

Immunohistochemistry (IHC) is a special test used by pathologists to detect specific molecules on cells. It is widely used in clinical oncology for categorizing solid cancer tumors and blood ...

From preclinical research to regulatory approval and clinical adoption, diagnostic testing underpins every stage of ADC ...

During a Case-Based Roundtable event, Laura Huppert, MD, discussed data and considerations around using T-DXd in breast ...

FGFR2b, fibroblast growth factor receptor 2 isoform IIIb; H&E, hematoxylin and eosin; IHC, immunohistochemistry. Fig 3. Examples of FGFR2b IHC staining with different collection methods. H&E and ...

Enhertu is a HER2-directed antibody and topoisomerase inhibitor conjugate. Approval of the new indication was based on data from the phase 3 DESTINY-Breast06 trial (ClinicalTrials.gov Identifier: ...

Findings showed datopotamab deruxtecan reduced the risk of disease progression or death by 37% compared with chemotherapy.

The approach requires balance, however. There is the risk of increased AEs, as well as financial toxicity. Friedlander shared ...

The PATHWAY HER2 (4B5) test is now FDA-approved to assess HER2-ultralow status in metastatic breast cancer, expanding its ...

Concordance between human epidermal growth factor receptor 2 (HER2) status by immunohistochemistry (IHC) and next-generation sequencing (NGS) in tissue and blood samples from gastric and ...

Komen advocacy organization. HER2-ultralow is defined as immunohistochemistry (IHC) 0 with membrane staining. T-DXd, an antibody-drug conjugate now approved for multiple tumor types, gained ...